Virtu Financial LLC acquired a new position in shares of GSK plc (NYSE:GSK – Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 9,154 shares of the pharmaceutical company’s stock, valued at approximately $339,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Horizon Bancorp Inc. IN grew its stake in GSK by 8.9% during the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock worth $147,000 after buying an additional 323 shares during the last quarter. Cerity Partners LLC grew its stake in GSK by 305.7% during the 4th quarter. Cerity Partners LLC now owns 118,233 shares of the pharmaceutical company’s stock worth $4,383,000 after buying an additional 89,089 shares during the last quarter. JPL Wealth Management LLC bought a new position in GSK during the 4th quarter worth $1,129,000. Dimensional Fund Advisors LP grew its stake in GSK by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,777,695 shares of the pharmaceutical company’s stock worth $65,883,000 after buying an additional 18,585 shares during the last quarter. Finally, International Assets Investment Management LLC bought a new position in shares of GSK in the fourth quarter worth $7,024,000. 15.74% of the stock is currently owned by institutional investors.
GSK Trading Up 0.7 %
Shares of GSK stock opened at $40.95 on Thursday. The stock has a 50-day simple moving average of $42.56 and a 200 day simple moving average of $41.03. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The stock has a market capitalization of $84.87 billion, a P/E ratio of 14.84, a P/E/G ratio of 1.23 and a beta of 0.66. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15.
GSK Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be paid a $0.3762 dividend. This is an increase from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 annualized dividend and a yield of 3.67%. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio is currently 53.26%.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on GSK. The Goldman Sachs Group began coverage on GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price target for the company. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.
Get Our Latest Analysis on GSK
GSK Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
See Also
- Five stocks we like better than GSK
- Using the MarketBeat Dividend Tax Calculator
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- How to Calculate Return on Investment (ROI)
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- 10 Best Airline Stocks to Buy
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.